An increase in the percentage of HLA-DR-positive peripheral leukocytes predicts a poor prognosis in patients with squamous cell carcinoma of the lung

Oncology Reports

Volumn 11, Issue 3, 2004, Pages 673-676

  Nakamura, Haruhiko ^a   Idiris, Aute ^a   Kato, Yasufumi ^a   Kato, Harubumi ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

HLA DR; Leukocyte; Lung cancer; Squamous cell carcinoma; Survival; Tumor immunity

Indexed keywords

HLA DR ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKOCYTE; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; LEUKOCYTES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TREATMENT OUTCOME;

EID: 4644245338     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.3.673     Document Type: Article

References (28)

1. Nakamura H, Kawasaki N, Hagiwara M, Saito M, Konaka C and Kato H: Cellular immunologic parameters related to age, gender, and stage in lung cancer patients. Lung Cancer 28: 139-145, 2000. (Pubitemid 30136413)
2. Nakamura H, Saji H, Ogata A, et al: Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 37: 161-169, 2002. (Pubitemid 34831808)
3. Wanebo H, Rao B, Miyazawa N, et al: Immune reactivity in primary carcinoma of the lung and its relation to prognosis. J Thorac Cardiov Sur 72: 339-350, 1976.
4. Dalbow M, Concannon J, Eng J, Weil C, Conway J and Narayanan NP: Lymphocyte mitogen stimulation studies for patients with lung cancer: evaluation of prognostic significance of preirradiation therapy studies. J Lab Clin Med 90: 295-302, 1977. (Pubitemid 8167910)
5. Cannon G, Dean J, Herberman R, et al: Association of depressed postoperative lymphoproliferative responses to alloantigens with poor prognosis in patients with stage I lung cancer. Int J Cancer 25: 9-17, 1980. (Pubitemid 10210718)
6. Braun D, Nisius S, Hollinshead A and Harris J: Serial immune testing in surgically resected lung cancer patients. Cancer Immunol Immunother 15: 114-120, 1983. (Pubitemid 13033190)
7. Lin C, Kuo Y, Huang W and Lin C: Natural killer cell activity in lung cancer patients. Chest 92: 1022-1024, 1987. (Pubitemid 18026540)
8. Mountain C: Revisions in the International System for Staging LungCancer. Chest 111: 1710-1717, 1997.
9. Nakamura H, Kawasaki N, Hagiwara M, Ogata A and Kato H: Endoscopic evaluation of centrally located early squamous cell carcinoma of the lung. Cancer 91: 1142-1147, 2001. (Pubitemid 32295419)
10. Cheadle W: The human leukocyte antigens and their relationship to infection. Am J Surg 165: S75-S81, 1993.
11. Hershman M, Cheadle W, Wellhausen S, Davidson P and Polk H: Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 77: 204-207, 1990. (Pubitemid 20055846)
12. Cheadle W, Hershman M, Wellhausen S and Polk H: HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 161: 639-645, 1991.
13. Ditschkowski M, Kreuzfelder E, Rebmann V, et al: HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. Ann Surg 229: 246-254, 1999. (Pubitemid 30191799)
14. -phenotype is associated with a prognosis in patients with lung cancer. Anticancer Res (In press).
15. Cole W: Relationship of causative factors in spontaneous regression of cancer to immunologic factors possibly effective in cancer. J Surg Oncol 8: 391-411, 1976.
16. Blades B and McCorkle R: A case of spontaneous regression of an untreated bronchogenic carcinoma. J Thorac Surg 27: 415-419, 1954.
17. Bell J, Jesseph J and Leighton R: Spontaneous regression of bronchogenic carcinoma with five year survival. J Thorac Cardiov Sur 48: 984-990, 1964.
18. Smith A: Cure of lung cancer from incomplete surgical resection. BMJ 5: 563-565, 1971.
19. Sperduto P, Vaezy A, Bridgman A and Wilkie L: Spontaneous regression of squamous cell lung carcinoma with adrenal metastasis. Chest 94: 887-889, 1988.
20. Tisch M, Kyrberg H, Weidauer H, et al: Human leukocyte antigens and prognosis in patients with head and neck cancer: results of a prospective follow-up study. Laryngoscope 112: 651-657, 2002. (Pubitemid 34285931)
21. + activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int J Cancer 61: 470-474, 1995.
22. Kikuchi Y, Iwano I, Kita T, et al: Changes of lymphocyte subsets in peripheral blood before and after operation of patients with advanced ovarian carcinoma. J Cancer Res Clin Oncol 116: 283-287, 1990. (Pubitemid 20299172)
23. Arista M, Callopoli A, De Franceschi L, et al: Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma. Dis Colon Rectum 37: S30-S34, 1994. (Pubitemid 24079554)
24. Yamamura M, Modlin R, Ohmen I and Moy R: Local expression of antiinflammatory cytokines in cancer. J Clin Invest 91: 1005-1010, 1993. (Pubitemid 23095275)
25. + T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42: 1-8, 1996.
26. Huang M, Sharma S, Mao J and Dubinett S: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol 157: 5512-5520, 1996. (Pubitemid 126448972)
27. Ito N, Nakamura H, Tanaka Y and Ohgi S: Lung carcinoma: analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry. Cancer 85: 2359-2367, 1999. (Pubitemid 29244844)
28. Gerrard T, Dyer D and Mostowski H: IL-4 and granulocyte-macrophage colony-stimulating factor selectively increase HLA-DR and HLA-DP antigens but not HLA-DQ antigens on human monocytes. J Immunol 144: 4670-4674, 1990. (Pubitemid 20224101)